REVIEW

The γ_c family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response [version 1; peer review: 3 approved]

Rosanne Spolski, Daniel Gromer, Warren J. Leonard

Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA

V1 First published: 23 Oct 2017, 6(F1000 Faculty Rev):1872
<https://doi.org/10.12688/f1000research.12202.1>

Latest published: 23 Oct 2017, 6(F1000 Faculty Rev):1872
<https://doi.org/10.12688/f1000research.12202.1>

Abstract

Interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21 form a family of cytokines based on the sharing of a receptor component, the common cytokine receptor γ chain, γ_c , which is encoded by the gene mutated in humans with X-linked severe combined immunodeficiency (XSCID). Together, these cytokines play critical roles in lymphoid development, differentiation, growth, and survival as well as mediating effector function. Here, we provide an overview of the main actions of members of this cytokine family but then primarily focus on IL-2 and IL-21, discussing their dynamic interplay and contributions to a fine-tuned immune response. Moreover, we discuss the therapeutic utility of modulating their actions, particularly for autoimmunity and cancer.

Keywords

gamma chain cytokines, interleukins, IL-2, IL-21, XSCID

Open Peer Review

Approval Status

	1	2	3
version 1 23 Oct 2017			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Cecile King**, Garvan Institute of Medical Research, Darlinghurst, Australia
2. **Thomas Malek**, Miller School of Medicine, University of Miami, Miami, USA
3. **Michael Caligiuri**, The Ohio State University, Columbus, USA

Any comments on the article can be found at the end of the article.

Corresponding authors: Rosanne Spolski (spolskir@nhlbi.nih.gov), Warren J. Leonard (wjl@helix.nih.gov)

Author roles: **Spolski R:** Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Gromer D:** Writing – Original Draft Preparation, Writing – Review & Editing; **Leonard WJ:** Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: R.S. and W.J.L. are inventors on patents related to IL-21.

Grant information: This work was supported by the Division of Intramural Research, National Heart, Lung, and Blood Institute. D.G. was supported by the National Institutes of Health Medical Research Scholars Program.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Spolski R *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions.

How to cite this article: Spolski R, Gromer D and Leonard WJ. **The γ_c family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response [version 1; peer review: 3 approved]** F1000Research 2017, 6(F1000 Faculty Rev):1872 <https://doi.org/10.12688/f1000research.12202.1>

First published: 23 Oct 2017, 6(F1000 Faculty Rev):1872 <https://doi.org/10.12688/f1000research.12202.1>

Introduction: the γ_c system and its association with severe combined immunodeficiency

Interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15, and IL-21 form a family of four α -helical bundle type I cytokines that share the common cytokine receptor γ chain, γ_c , as a key receptor component (Figure 1)¹. γ_c is mutated in humans with X-linked severe combined immunodeficiency (XSCID), a disease in which T and natural killer (NK) cells are greatly diminished and B cells are non-functional². Finding the basis for XSCID immediately allowed more precise prenatal and postnatal diagnosis and carrier female identification as well as paving the way to gene therapy for this disease^{3,4}. In addition, the implications of this finding extended far beyond the management of a single disease and had major basic scientific implications as well. Although γ_c was initially discovered as the IL-2 receptor γ chain (IL-2R γ) and identifying the genetic basis for XSCID resulted from studies of the IL-2R, the fact that the phenotype in XSCID is more severe than in IL-2 deficiency led to the prediction and then discovery that IL-2R γ was in fact a shared receptor component^{5–8}, and the term γ_c was proposed⁵. Interestingly, the major phenotypic abnormalities do not result from defective IL-2 signaling; instead, defective signaling by IL-7 and IL-15 explain the profound decrease in T and NK cells, respectively, and defective IL-21 signaling substantially explains the non-functional B cells in this disease⁹. Thus, XSCID was established to be a disease of defective cytokine signaling¹⁰.

Each γ_c family cytokine activates the Janus family tyrosine kinases (JAK)1 and JAK3, which then trigger signaling cascades. JAK1 associates with the more distinctive type I cytokine receptor for each cytokine and JAK3 associates with γ_c . Because JAK3 is “downstream” of γ_c , it was hypothesized¹² and then established that JAK3-deficient SCID indeed occurs, causing a T⁺B⁺NK[−] form of SCID that phenocopies XSCID^{13,14}. Moreover, individuals with IL7R-deficient SCID were identified based on the prediction that such patients would have defective T cell development but that NK cells would develop normally given intact IL-15 signaling¹⁵. Although IL-7 signaling is believed to be responsible for the lack

of T cell development, to date human IL7-deficient SCID has still not been identified. Presumably, the frequency of inactivating mutations of IL7 is very low, the condition is unexpectedly lethal, or the phenotype is less severe than anticipated so that individuals do not come to medical attention. A less severe phenotype for IL7 than IL7R deficiency is conceivable given that signaling by thymic stromal lymphopoietin (TSLP) would also be affected in the latter but not the former, and indeed there is even more defective T cell development in mice lacking the expression of both γ_c and the TSLP receptor (IL2rg/Crlf2 double knockout mice) than in IL2rg single knockout mice¹⁶. However, XSCID and JAK3-deficient patients have intact TSLP signaling but nevertheless have essentially absent T cell development, minimizing this as an explanation.

STAT activation and major biological effects of γ_c family cytokines

γ_c family cytokines collectively have broad actions (Table 1) and activate three major signaling pathways, including the MAP kinase, PI 3-kinase, and JAK–STAT (signal transducer and activator of transcription) pathways. Of the seven STAT proteins, IL-2 mainly activates STAT5A and STAT5B, but it also signals through STAT1 and STAT3 to some degree¹⁷ (see Figure 1 for STATs activated by each γ_c family cytokine). It is a T cell growth factor that additionally augments the cytolytic activity of CD8⁺ T cells and NK cells and is essential for regulatory T (Treg) cell development¹⁸. It also promotes the differentiation of T helper type 1 (Th1)¹⁹, Th2^{20,21}, and Th9 cells²² while inhibiting Th17 cell differentiation^{19,23}. Importantly, from a clinical perspective, IL-2 exhibits anti-cancer activity and is approved by the FDA for the treatment of melanoma and renal cell carcinoma²⁴.

IL-4 mainly activates STAT6 and plays major roles in allergic responses, including asthma and in protection against helminth infections^{25–28}. IL-4 signals via two types of receptor. Type I IL-4 receptors (IL-4Rs) comprise IL-4R α plus γ_c ⁶ and are expressed mainly on lymphoid cells. In contrast, type II IL-4Rs comprise IL-4R α plus IL-13R α 1 (but not γ_c) and are mainly expressed on

Figure 1. γ_c family cytokines and their receptors. Shown is the receptor for each γ_c family cytokine as well as the interacting Janus kinase 1 (JAK1) and JAK3 kinases and the signal transducer and activator of transcription (STAT) proteins activated by each cytokine. DC, dendritic cell; IL, interleukin.

Table 1. Actions of γ_c family cytokines.

IL-2	<ul style="list-style-type: none"> • Promotes Th1, Th2, and Th9 differentiation and antagonizes Th17 and Tfh differentiation • Induces T cell and NK cell proliferation • Enhances Treg cell differentiation and function • Anti-cancer role for immunotherapy
IL-4	<ul style="list-style-type: none"> • Promotes B cell differentiation and Ig isotype switching • Promotes Th2 and Th9 differentiation • Proliferative effects on tissue-resident macrophages • Protection from helminth infection
IL-7	<ul style="list-style-type: none"> • Required for T cell development and homeostasis • Promotes memory CD8⁺ T cell development • Essential for B cell development in mice but dispensable for B cell development in humans
IL-9	<ul style="list-style-type: none"> • Promotes mast cell proliferation • Augments mucus production by goblet cells • Anti-tumor activity
IL-15	<ul style="list-style-type: none"> • Essential for NK development, expansion, and survival • Promotes memory CD8⁺ T cell development • Anti-cancer role for immunotherapy via actions on CD8⁺ T cells and NK cells
IL-21	<ul style="list-style-type: none"> • Promotes B cell differentiation to plasma cells and augmenting Ig production • Has anti-cancer activity mediated in part via actions on CD8⁺ T cells and NK cells • Promotes Tfh differentiation and germinal center formation • Promotes Th17 differentiation • Inhibits Th9 differentiation • Promotes autoimmune disease (type 1 diabetes, SLE, EAE, and colitis)

EAE, experimental autoimmune encephalomyelitis; Ig, immunoglobulin; IL, interleukin; NK, natural killer; SLE, systemic lupus erythematosus; Tfh, T follicular helper; Th, T helper; Treg, T regulatory.

non-lymphoid cells; these IL-4Rs also represent the functional IL-13 receptor^{28,29}.

IL-7 is a stromal factor which, like IL-2, predominantly activates STAT5A and STAT5B^{17,30}. It drives T cell development as well as normal CD8⁺ T cell homeostasis, particularly of memory CD8⁺ T cells. IL-7 is a potent survival factor for T cells, strongly inducing the expression of BCL2^{31–34}. Unlike other γ_c family cytokines, IL-7 is produced within the stroma and is more constitutively expressed.

IL-9 also activates STAT5A and STAT5B^{17,30}. This cytokine can promote the expansion of mast cells. Interestingly, a single nucleotide polymorphism (SNP) in the *IL9R* gene associates with a haplotype that is protective against wheezing in boys but not in girls³⁵; this sex-related difference makes sense given that *IL9R* is located on the X chromosome. IL-9 also promotes anti-tumor immunity^{36,37}.

Like IL-2, IL-15 primarily activates STAT5A and STAT5B¹⁷ and shares IL-2R β as well as γ_c as receptor components. Like IL-2, IL-15 also has a specific α chain, IL-15R α , so that these two cytokines each have three receptor components. However, whereas IL-2 signals mainly *in cis* by interacting with high-affinity IL-2 receptors that contain IL-2R α , IL-2R β , and γ_c or intermediate-affinity receptors comprising IL-2R β and γ_c , IL-15 primarily signals via trans-presentation of IL-15R α -bound IL-15 to cells expressing IL-2R β and γ_c ³⁸. IL-15 is critical for the development and expansion of NK cells as well as for memory CD8⁺ T cell homeostasis^{39,40}.

IL-21 is the most recently identified γ_c family cytokine. IL-21 has pleiotropic actions, driving the terminal differentiation of B cells to plasma cells^{41,42} and cooperating with IL-7 and IL-15 to expand CD8⁺ T cells⁴³. Moreover, IL-21 serves a key role in promoting T follicular helper (Tfh) cell differentiation⁴⁴ and can augment Th17 differentiation *in vitro*^{45–47}. Furthermore, IL-21 has anti-cancer activity in animal models and is being evaluated in human clinical trials. In addition, a broad range of animal models indicate that IL-21 plays a key role in the development of autoimmune disease, including for type 1 diabetes, systemic lupus erythematosus, and experimental autoimmune uveitis⁴⁸. Collectively, γ_c family cytokines therefore play broad and important biological roles, many of which are associated with diseases and may represent targets for therapeutic application. Below, we will focus on IL-2 and IL-21, which exhibit both overlapping and opposing actions.

IL-2 and IL-21

IL-2 and IL-21 are encoded by adjacent genes on human chromosome 4q27 and mouse chromosome 3, and their structural homology suggests that these two genes may have arisen from a gene duplication event during evolution. Despite their proximity, the *IL2* and *IL21* genes are differentially regulated, and analysis of the chromatin region between these genes has revealed the presence of insulator regions that ensure their independent regulation^{49,50}. IL-2 and IL-21 exert distinctive actions on immune cell populations, sometimes with opposite outcomes, which results, at least in part, from their differential activation of STAT proteins. Although both cytokines can activate STAT1, STAT3,

STAT5A, and STAT5B, IL-2 predominantly activates STAT5A and STAT5B, whereas IL-21 mostly signals via STAT3. Consistent with these signaling differences, analysis of the effects of IL-2 and IL-21 on the anti-tumor activity of CD8⁺ T cells revealed that these cytokines induced distinctive transcriptional profiles, with associated differences in disease outcome⁵¹. Whereas IL-2 enhanced CD8⁺ T cell proliferation and effector function, IL-21-treated cells exhibited a central memory phenotype, with greater persistence of the cells and higher anti-tumor activity *in vivo*. IL-2 and IL-21 also have markedly different effects on the *in vivo* function of Tfh cells and the *in vitro* differentiation of Th9 cells, as we discuss below. As continued investigation yields more insights into the mechanistic underpinnings of these two cytokines, investigators may learn how to specifically enhance the “good” features and inhibit the “bad” features of each. Here, we review recent advances in our understanding of IL-2 and IL-21, how they regulate multiple lymphoid populations, and potential strategies for utilizing the strengths of each cytokine in the treatment of disease.

IL-2 signaling

As noted above, each γ_c family cytokine can activate the JAK–STAT pathway, but these cytokines collectively also activate phosphoinositide (PI) 3-kinase and extracellular signal-regulated kinase (ERK)-dependent pathways as well¹⁸. The relative kinetics and potency of activation of JAK–STAT, PI 3-kinase, and ERK pathways and the kinetics of their activation are critical for determining the specificity of signaling. Each of these three major signaling pathways involves kinases, and IL-2, like other cytokines and growth factors, influences the exchange of phosphate groups. Understanding the mechanisms that these intracellular systems use to initiate specific differentiation programs, often by increasing the expression of key transcriptional regulators, represents a major step towards creating future interventions to alter cell fate¹⁸.

Using mass spectrometry, a phosphoproteomic signature was recently identified in pre-activated CD8⁺ T cells that were cultured with IL-12 to maintain viability and then stimulated with IL-2⁵². IL-2 was shown to induce the phosphorylation and dephosphorylation of a large number of proteins that carry out vital functions, including transcription, RNA stabilization, nuclear translocation, protein translation, cell trafficking, metabolism, and cell cycle, thus potentially identifying new targets for manipulating IL-2 signaling. Surprisingly, inhibition of JAK3 and JAK1 signaling with tofacitinib affected only 4% of the phosphoproteome, suggesting that many of these phosphorylation events were independent of JAK signaling⁵². Interestingly, Treg cells have been shown to express high levels of phosphatase and tensin homolog (PTEN)⁵³, which inhibits IL-2-induced PI 3-kinase signaling but does not affect STAT5 activation. PTEN thus may be differentially important in the control of IL-2-mediated Treg cell versus effector T cell function. Consistent with this possibility, the absence of PTEN can reduce IL-2R α and FoxP3 expression by Treg cells, leading to autoimmune disease⁵³.

Investigators have also studied IL-2 diffusion through cell “niches” as measured by STAT5 phosphorylation in target cells⁵⁴. By using IL-2/anti-IL-2 complexes to expand Treg cells *in vivo* and

assessing STAT5 signaling in conventional T cells, it was shown that the dimensions of cytokine gradients changed rapidly, depending on the number of cells (e.g., Treg cells) that were consuming cytokine. The IL-2 gradients identified suggest that there may be functional heterogeneity in response to antigen and cytokine signals, depending on the position of responding cells in three-dimensional space within a given organ⁵⁴, with possible therapeutic implications for manipulating IL-2 concentrations *in vivo*.

Manipulating IL-2 signals in immunotherapy

The anti-cancer activity of IL-2 has long been known, and high-dose IL-2 can be toxic and is associated with capillary leak syndrome; thus, efforts to lower the toxicity have focused in part on lowering IL-2⁵⁴. IL-2 can also promote activation-induced cell death (AICD), an unwanted effect that can be diminished by lowering doses of IL-2. Previous studies showed that in addition to it inducing the proliferation of CD8⁺ T cells, IL-2 preferentially stimulates short-lived effector T cells that are detrimental to cancer immunotherapy⁵¹. IL-15 is another important cytokine for immunotherapy that, unlike IL-2, does not bind to IL-2R α and thus does not preferentially stimulate Treg cells. Unlike IL-2, IL-15 is not associated with capillary leak syndrome nor does it mediate AICD^{55,56}. Despite these potential advantages for IL-15, IL-2–anti-IL-2 complexes were superior to IL-15–soluble IL-15R α complexes at supporting the anti-tumor activity of transferred CD8⁺ T cells⁵⁷. One basis for this could be that IL-15 is quickly internalized and mediates only brief STAT5 signaling in a lymphoreplete host, whereas IL-2 remains in a surface “reservoir”, trapped by excess IL-2R α and recycled after internalization, which results in sustained STAT5 signaling⁵⁷. Indeed, a membrane-tethered form of IL-15 on tumor-specific T cells demonstrated improved T cell survival and enhanced anti-tumor effects *in vivo* due to the preferential growth of T memory stem cells⁵⁸. Thus, both IL-2 and IL-15 show considerable potential that is worthy of additional investigation.

Another strategy for improving immunotherapeutic outcomes in malignancy involves disabling or eliminating tumor-associated Treg cells. Effector T cells within tumors have much lower expression of IL-2R α (CD25) than do Treg cells, suggesting that targeting CD25 might be a therapeutically useful approach for preferentially depleting Treg cells⁵⁹. Although earlier attempts to deplete intratumoral Treg cells with antibodies to CD25 were not successful^{60,61}, a new CD25-directed antibody with enhanced binding to an activating Fc region allowed Treg cell-specific antibody-dependent cell-mediated cytotoxicity (ADCC) (Figure 2A), and when combined with a programmed death-1 (PD-1) blockade in mice, this treatment skewed the tumor-infiltrating lymphocyte (TIL) landscape towards activated, conventional T cells and improved rejection of established tumors⁵⁹.

Because IL-2 drives CD8⁺ T cells toward an “effector” phenotype, which confers poor anti-tumor performance in some models, reducing IL-2 signaling favors the production of memory CD8⁺ T cells^{62,63}. A new strategy for reducing IL-2 signaling is to conjugate *Il2ra* siRNAs to a 4-1BB-binding oligonucleotide aptamer. Since 4-1BB is expressed on activated CD8⁺ T cells, this approach was designed to decrease IL-2 signaling specifically on these cells (Figure 2B).

Figure 2. Schematic for mechanisms of manipulating interleukin (IL)-2 signals. (A) CD25-specific antibody with an activating Fc region binds to CD25 on regulatory T (Treg) cells and activates natural killer (NK)-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) via stimulation of the FcR. (B) Silencing RNAs to *Il2ra* are conjugated to an aptamer that allows specific binding to 4-1BB on CD8⁺ T cells, allowing delivery specifically to activated cells. siRNA, small interfering RNA.

Indeed, this aptamer increased “central memory” phenotype cells *in vitro* and enhanced tumor rejection in mice, demonstrating its potential efficacy⁶⁴.

Above, we discussed ways of modulating IL-2 signaling by efforts to diminish the expression of CD25 in conventional T cells, deplete CD25^{high} Treg cells, or to increase the availability of IL-2, either locally or systemically. The effects of complexes of IL-2 and IL-2-specific antibodies have also been studied. One monoclonal antibody binds with high affinity to human IL-2 at the CD25-binding epitope, thus preventing interaction with high-affinity receptors. Instead, the stabilized IL-2–anti-IL-2 complex preferentially acts on cells with a high level of IL-2Rβ–γ_c intermediate-affinity receptors, such as NK and CD8⁺ T cells, inducing their proliferation and STAT phosphorylation, decreasing TIL markers of “exhaustion”, and improving anti-tumor responses⁶⁵. Other IL-2–anti-IL-2 complexes can selectively stimulate either Treg or effector T cells, and protein interaction modeling coupled with biological experiments allows the engineering of therapeutic antibodies directed at specific immune subpopulations⁶⁶.

Besides the anti-cancer actions of IL-2, augmenting *in vivo* T cell exposure to IL-2 might be beneficial in vaccine strategies or in efforts to treat autoimmune disease. In one approach, IL-2 plasmid was co-administered with human papillomavirus (HPV) vaccination of mice, which increased the proliferation and effector differentiation of HPV E7-specific CD8⁺ T cells and their

production of interferon (IFN)γ. Importantly, this augmented the ratio of effector cells to Treg cells, with an enhanced anti-tumor response⁶⁷.

Another approach to enhance the activity of IL-2 was to develop an IL-2 superkine with augmented affinity for IL-2Rβ⁶⁸. Normally, IL-2 first binds IL-2Rα, resulting in a conformational change in IL-2 that allows it to then efficiently bind IL-2Rβ; the IL-2–IL-2Rβ complex then efficiently recruits γ_c. The IL-2 superkine “locks in” the altered conformation that normally results after binding IL-2Rα so that it efficiently binds to IL-2Rβ, even in the absence of IL-2Rα⁶⁸. This superkine had increased activity, even at a low concentration, with decreased capillary leak syndrome⁶⁸. Derivatives of the IL-2 superkine have also been generated in order to fine-tune IL-2 signaling (discussed below)⁶⁹.

Using IL-2 to preferentially expand Treg cells constitutes an area of intense focus related to autoimmune disease. For example, providing low doses of IL-2 to patients with systemic lupus erythematosus (SLE) can increase the percentage of circulating Treg cells and may prove clinically beneficial⁷⁰. An initial study in which patients with SLE were given low-dose IL-2 reported an increase in the number of Treg cells, which was associated with an apparent decrease in a clinical SLE disease index⁷¹, suggesting that such an approach may warrant evaluation in future clinical trials. A similar IL-2 regimen in mice resulted in augmented PD-1 expression in an “activated-memory” Treg cell subset, and PD-1 blockade resulted in apoptosis of these cells. Low-dose IL-2 treatment of humans with graft-versus-host disease was originally found to lead to expansion of Treg cells and reduced symptoms in a group of patients⁷². Moreover, humans with graft-versus-host disease receiving low-dose IL-2 treatment could be retrospectively divided into likely responders and non-responders based on PD-1 expression on their peripheral Treg cells⁷³.

Effects of IL-21 on germinal center T cells

IL-21 is a key regulator of T follicular helper (Tfh) cell development in germinal centers and represents a major cytokine secreted by Tfh cells that critically regulates the differentiation of memory B cells and plasma cells⁴⁴. Tfh cells appear to be heterogeneous with regard to their cytokine profiles and their anatomical location^{74,75}. For example, when IL-4–IL-21 double reporter mice were infected with *Nippostrongylus brasiliensis*, few Tfh cells produced both IL-4 and IL-21, and those producing either IL-4 or IL-21 were localized to different regions of the germinal center. Tfh cells expressing IL-4, IL-21, or both cytokines also had distinct transcriptional profiles⁷⁶. Interestingly, in the germinal center, IL-21-producing Tfh cells, which are localized at a region involved in immunoglobulin (Ig) hypermutation, can differentiate into IL-4-producing Tfh cells, which are localized in an area more involved in the differentiation of plasma cells. When these individual Tfh populations were transferred into mice and immunized, Tfh cells producing IL-21 or IL-21 plus IL-4 induced higher expression of B-cell lymphoma 6 protein (BCL6) in the germinal center, with the cells producing both cytokines inducing a greater increase in germinal center size and more plasma cells⁷⁶, consistent with the synergistic effects of IL-4 and IL-21, as was first shown for immunoglobulin (Ig) production⁹.

Tfh cells do not appear to be restricted to classical secondary lymphoid organs, as a population of these cells has also been identified in Peyer's patches of the intestine⁷⁷. These Tfh cells produce high levels of IL-21, which is essential for the production of IgG1 by germinal center B cells in the intestine. Treatment of mice with antibiotics led to a dramatic decrease in the number of Tfh cells within the Peyer's patches, indicating that an intact gut microbiome is required for the maintenance of these cells. Not only are Tfh cells capable of differentiating or migrating outside of the spleen and lymph nodes but they can also exhibit functional plasticity. For example, when animals were exposed to house dust mite allergen and IL-21-expressing Tfh cells from these mice were then transferred into other primed mice, they migrated to the lung where they lost expression of IL-21 and differentiated into effector Th2 cells that expressed both IL-4 and IL-13⁷⁸.

Interestingly, high production of IL-21 has been detected in populations of Tfh and Tfh-like cells that are external to germinal centers, and these cells can also regulate B cell activation and Ig production. For example, high levels of peripheral Tfh cells that secrete high levels of IL-21 have been found in a subset of HIV-infected patients, and the presence of this population correlated with an effective response to influenza vaccine⁷⁹. In addition, a population known as T peripheral helper (Tph) cells, comprising 30% of synovial fluid CD4⁺ T cells in rheumatoid arthritis patients, expresses chemokine receptors (CCR2, CX3CR1, CCR5) that allow the cells to migrate to sites of inflammation⁸⁰. In contrast to Tfh cells localized in germinal centers, Tph cells are PD-1^{hi} but are not exhausted, and they express high levels of B lymphocyte-induced maturation protein 1 (BLIMP1) but low levels of BCL6. Moreover, Tph and Tfh cells have not been interconverted *in vitro*, suggesting that Tph cells develop *in vivo* to induce B cell responses in pathological situations, such as within inflamed synovium⁸⁰.

IL-21 can also influence another small population of cells in the germinal center, known as T follicular regulatory (Tfr) cells, which negatively regulate Tfh-directed germinal center responses^{81–83}. These Tfr cells share some phenotypic markers (CXCR5⁺BCL6⁺ICOS⁺PD1⁺) with Tfh cells, but they also express the transcription factor FoxP3. Tfr cells can interact directly with Tfh cells to suppress their production and secretion of IL-21 and IL-4, thereby decreasing B cell Ig production⁸⁴. Tfr cells can also interact directly with B cells in the germinal center, inhibiting several metabolic pathways and diminishing their effector function⁸⁴. IL-21 can overcome the effects of Tfr, both by inhibiting their proliferation and by upregulating glycolysis in B cells, making them resistant to suppression by Tfr. Although IL-4 plays an important role in germinal center B cell responses, unlike IL-21, it cannot overcome Tfr-mediated suppression⁸⁴.

IL-21 versus IL-2 effects on regulating CD4⁺ T cell responses within the germinal center

As noted above, IL-2 and IL-21 are differentially regulated and have distinct effects on immune responses. Indeed, these cytokines may even have opposing effects on the formation of the cell populations within the germinal center that contribute to the generation

of a humoral response to pathogens. Within the germinal center, Tfh and B cells interact with each other via IL-21 and ICOS: ICOS ligand interactions, leading to high expression of BCL6 by Tfh cells and the specification of the Tfh cell transcriptional profile (Figure 3). Although IL-2 can expand effector T cell populations¹⁸, interestingly, it can suppress the generation of Tfh cells within the germinal center in an influenza infection model⁸⁵. This inhibitory effect of IL-2 on Tfh cell generation was not due to the accumulation of Treg cells but rather was attributed to the ability of IL-2 to induce BLIMP1, which suppresses BCL6. Thus, whereas IL-21 induces BCL6 and promotes the accumulation of Tfh cells, IL-2 suppresses BCL6 and inhibits the germinal center response.

Figure 3. Roles of interleukin (IL)-2 and IL-21 in the regulation of germinal center development and function. IL-21 drives T follicular helper (Tfh) differentiation and function through the upregulation of B-cell lymphoma 6 protein (BCL6); moreover, it also induces the differentiation of B cells to immunoglobulin (Ig)-producing plasma cells through the upregulation of the B lymphocyte-induced maturation protein 1 (BLIMP1). IL-2 negatively regulates this process by inhibiting Tfh cell generation through the repression of BCL6 and also by inducing the function of T follicular regulatory (Tfr) cells that can directly interact with and inhibit B cell differentiation. AID, activation-induced deaminase; CTLA4, cytotoxic T lymphocyte-associated molecule-4; CXCR5, C-X-C chemokine receptor type 5; ICOS, inducible costimulator ligand; IFN, interferon; IL, interleukin; PD1, programmed death protein 1; PDL1, programmed death ligand 1.

Interestingly, mounting evidence suggests that CD4⁺ T cells destined to become Tfh cells are guided to a niche where IL-2 cannot alter their course of differentiation. These cells exhibit a G-protein-coupled receptor, EB12, that promotes migration to the “outer T zone”, and they co-localize with CD4⁺ dendritic cells that consume free IL-2 with soluble and transmembrane CD25⁸⁶. This is consistent with the evolving model of antagonistic actions for IL-2 and IL-21 at the germinal center and that opposing effects of IL-2 and IL-21 are physiologically relevant.

Other studies have used an acute lymphocytic choriomeningitis virus (LCMV) infection model to dissect the dynamics of signaling and metabolism in Tfh and Th1 cells. As noted above, IL-2 inhibits Tfh differentiation but promotes Th1 differentiation. Activation of AKT, PI 3-kinase, and the mechanistic target of rapamycin (mTOR) by IL-2 was necessary for the generation of optimal levels of phospho-S6 and BLIMP-1, which by repressing the transcription of BCL6 can decrease Tfh cell differentiation. Additionally, the expression of T-Bet, a master regulator of Th1 differentiation, depends on AKT and Raptor (mTORc1)⁸⁷. Interestingly, Tfh cells in the LCMV infection model relied more on mitochondrial oxidation pathways and were less proliferative and less glycolytic than Th1 cells, although the significance of these observations remains unclear.

Although IL-2 signaling inhibits the germinal center response, as noted above, IL-2 induces the survival and function of Treg cells, which suppress both humoral and cellular immune responses⁸⁸. It was therefore surprising that when FoxP3⁺ Treg cells were depleted from mice prior to influenza infection, the Tfh cell response to virus infection was greatly reduced⁸⁹. Without Treg cells to bind and consume IL-2, more IL-2 was available to suppress Tfh cell generation and functional germinal center responses. Thus, under steady-state conditions, Treg cells with their high CD25 expression can compete for excess IL-2 in the follicle and promote the Tfh response. However, when IL-2 levels are sufficiently high, Tfh cell generation is suppressed.

Above, we showed an interplay between IL-21 and IL-2 related to Treg cells and Tfh cells, and indeed previous studies in mice had demonstrated that IL-21 inhibited Treg expansion after viral infection⁹⁰. While IL-2 enhances the survival of FoxP3⁺ Treg cells, IL-21 diminishes IL-2 production by conventional T cells and thereby lowers Treg cell numbers⁹¹. As a result, one would predict that humans depleted of IL-21 would have increased Treg cells. In fact, *IL21R*-deficient patients have high numbers of both Treg cells and Tfr-like cells in their peripheral blood, suggesting that these populations are normally negatively regulated by IL-21⁹². Mechanistically, IL-21 induces BCL6 and lowers *IL2RA* gene expression, leading to a decrease in the ability of inhibitory Treg and Tfr cells to proliferate in response to IL-2, with a correspondingly more robust germinal center antibody response⁹².

Opposing actions of IL-2 and IL-21 in Th9 differentiation

IL-2 and IL-21 can drive alternative and sometimes opposing differentiation programs in a range of cell types, including the stimulatory and inhibitory germinal center populations noted

above. Another example of opposing actions for these cytokines is in the differentiation of IL-9-producing Th9 cells. These cells, which were initially characterized as a population generated by stimulation with transforming growth factor (TGF)β and IL-4, have been shown to play a role in multiple inflammatory disease processes as well as in anti-tumor responses⁹³. IL-2 is known to promote the development of IL-9-producing cells⁹⁴, and details of the mechanisms involved have been elucidated^{22,95}. IL-2-mediated activation of STAT5 is required for IL-9 production, with STAT5 binding at the *Il9* promoter. In contrast, IL-21 negatively regulates the initial production of IL-9, at least in part owing to the induction of transcription factor BCL6, which binds to the *Il9* promoter in close proximity to STAT5, suggesting that STAT5 and BCL6 compete for access to these promoter sites²². Consistent with direct effects of IL-2-induced STAT5 signals on IL-9 transcription, mice deficient for *Itk*, a Tec family kinase activated via the T cell receptor, had defective production of interferon regulatory factor 4 (IRF4) and IL-9 production, and the expression of these factors could be rescued by IL-2 or constitutively activated STAT5⁹⁶.

Unlike STAT5, STAT3 activation has been shown to negatively regulate both the initiation and the maintenance of IL-9 expression. Th9 cells subjected to multiple rounds of *in vitro* differentiation produced increasing amounts of IL-21 and IL-10, which then led to the extinction of IL-9 production⁹⁷. It remains to be determined whether this effect is relevant *in vivo*, but in this regard, IL-1β could induce the production of high levels of IL-21 by Th9 cells, but these cells nevertheless continued to produce IL-9 and acquired potent IL-21-mediated anti-tumor activity⁹⁸.

IL-2 was also reported to contribute to the pathogenic role of IL-9 in lung disease and inflammation in cystic fibrosis through a self-amplifying circuit involving IL-2⁹⁹. In this circuit, lung epithelial damage resulted in the release of IL-33, which induced the expansion of innate lymphoid cells (ILCs) and their production of IL-9, which triggered mast cells to secrete IL-2. The mast cell-produced IL-2 then further expanded both CD25⁺ ILC2s as well as Th9 cells in the lung, promoting the ongoing inflammatory process.

Fine-tuning of cytokine signals

Above we have discussed a range of physiological effects and potential therapeutic approaches using IL-2 and IL-21 and provided examples where they can oppose each other's actions. These are illustrative, and many of the lessons learned in these studies can be extended to other systems. It is important to underscore that differential actions for single cytokines have been noted and fine actions of the cytokines can be attributed to the utilization of different STAT proteins—for example, where one cytokine exhibits the induction of different genes depending on which STAT is activated. For instance, IL-21 mainly acts via the activation of STAT3⁴³, yet it induces some genes, such as *Tbx21* encoding T-Bet and *Ifng*, via STAT1, with STAT3 opposing their induction¹⁰⁰. Differential STAT utilization thus represents a mechanism for fine-tuning the signaling induced by a single cytokine. In addition, IL-2 and IL-21 differentially regulate Th9, Tfh, and

Th17 differentiation, providing an example of fine-tuning based on which cytokine is dominant in a given context. Another mechanism of fine-tuning can occur at the level of STAT tetramerization. For example, IL-2 activates STAT5A and STAT5B to form dimers (homodimers and potentially heterodimers) as well as tetramers (potentially both homotetramers and a range of heterotetramers)¹⁰¹. Tetramerization occurs via dimerization of STAT dimers, mediated by an N-terminal region known as the N-domain. Some genes require STAT5 tetramers for their normal expression, whereas STAT5 dimers are sufficient for viability, red cell production, and normal thymic development. Interestingly, STAT5 tetramer-deficient mice have diminished numbers of CD8 and NK cells, defective proliferation, including in response to infection with LCMV, and diminished (albeit not absent) Treg cell function¹⁰¹.

In addition to these physiological mechanisms of fine-tuning signals, IL-2 partial agonists have now been generated. The IL-2 superkine⁶⁸, which exhibits enhanced binding to IL-2R β , was used as a background for selecting mutants that exhibited diminished interaction with γ_c ⁶⁹. In contrast to the super-IL-2 full agonist, such molecules could either abrogate or attenuate IL-2 signaling based on the level of recruitment of γ_c , thereby altering the E_{max} and signaling threshold. Because these molecules have enhanced binding to IL-2R β , they outcompete endogenous IL-2 as well as IL-15 (which also shares IL-2R β) and confer a new level of signaling. One such molecule, denoted as H9-RETR, has four amino acid mutations and disrupts the γ_c binding interface completely. Not only can this molecule inhibit cytokine-induced STAT5 phosphorylation on T and NK cells but it also inhibits IL-2 or IL-15-induced cytolytic activity of NK cells *in vitro*, prolongs survival in a mouse model of graft-versus-host disease, and inhibits the proliferation of cells from patients with the chronic/smoldering form of human T-cell lymphotropic virus-I (HTLV-I)-induced adult T cell leukemia⁶⁹. The approach for generating these

partial agonists may be able to provide a range of interesting new IL-2 variants and should be broadly applicable to other cytokines as well.

Concluding remarks

The γ_c family of cytokines collectively serve critical roles in the immune system, controlling lymphocyte development, growth, differentiation, and survival. In this review, we have focused primarily on IL-2 and IL-21, clarifying ways in which they regulate the immune response physiologically as well as how they can be utilized and manipulated to modulate the immune system in disease settings. Novel approaches, including the generation of new variants of IL-2 such as an IL-2 superkine or IL-2 partial agonists or the “stabilization” of IL-2 with anti-IL-2 antibodies with effects on binding specificity, show promise for modulating the actions of IL-2 and potentially IL-15 to therapeutic benefit.

Competing interests

R.S. and W.J.L. are inventors on patents related to IL-21.

Grant information

This work was supported by the Division of Intramural Research, National Heart, Lung, and Blood Institute. D.G. was supported by the National Institutes of Health Medical Research Scholars Program.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We thank Mr. Dalton Hermans for assistance with figure preparation.

References

- Rochman Y, Spolski R, Leonard WJ: **New insights into the regulation of T cells by γ_c family cytokines.** *Nat Rev Immunol.* 2009; 9(7): 480–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Noguchi M, Yi H, Rosenblatt HM, et al.: **Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans.** *Cell.* 1993; 73(1): 147–57.
[PubMed Abstract](#)
- Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M: **Gene therapy for primary adaptive immune deficiencies.** *J Allergy Clin Immunol.* 2011; 127(6): 1356–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Leonard WJ: **Cytokines and immunodeficiency diseases.** *Nat Rev Immunol.* 2001; 1(3): 200–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Noguchi M, Nakamura Y, Russell SM, et al.: **Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor.** *Science.* 1993; 262(5141): 1877–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Russell SM, Keegan AD, Harada N, et al.: **Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor.** *Science.* 1993; 262(5141): 1880–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kondo M, Takeshita T, Ishii N, et al.: **Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4.** *Science.* 1993; 262(5141): 1874–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kondo M, Takeshita T, Higuchi M, et al.: **Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes.** *Science.* 1994; 263(5121): 1453–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ozaki K, Spolski R, Feng CG, et al.: **A critical role for IL-21 in regulating immunoglobulin production.** *Science.* 2002; 298(5598): 1630–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Leonard WJ: **The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling.** *Annu Rev Med.* 1996; 47: 229–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Leonard WJ, O'Shea JJ: **Jaks and STATs: biological implications.** *Annu Rev Immunol.* 1998; 16: 293–322.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Russell SM, Johnston JA, Noguchi M, et al.: **Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID.** *Science.* 1994; 266(5187): 1042–5.
[PubMed Abstract](#) | [Publisher Full Text](#)

13. Macchi P, Villa A, Giliani S, *et al.*: **Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID).** *Nature*. 1995; 377(6544): 65–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Russell SM, Tayebi N, Nakajima H, *et al.*: **Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.** *Science*. 1995; 270(5237): 797–800.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Puel A, Ziegler SF, Buckley RH, *et al.*: **Defective IL7R expression in T^B·NK⁺ severe combined immunodeficiency.** *Nat Genet*. 1998; 20(4): 394–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Al-Shami A, Spolski R, Kelly J, *et al.*: **A role for thymic stromal lymphopoietin in CD4⁺ T cell development.** *J Exp Med*. 2004; 200(2): 159–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Lin JX, Migone TS, Tsang M, *et al.*: **The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15.** *Immunity*. 1995; 2(4): 331–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Liao W, Lin J, Leonard WJ: **Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.** *Immunity*. 2013; 38(1): 13–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. **F** Liao W, Lin J, Wang L, *et al.*: **Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages.** *Nat Immunol*. 2011; 12(6): 551–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
20. Cote-Sierra J, Fouches G, Guo L, *et al.*: **Interleukin 2 plays a central role in Th2 differentiation.** *Proc Natl Acad Sci U S A*. 2004; 101(11): 3880–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Liao W, Schones DE, Oh J, *et al.*: **Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression.** *Nat Immunol*. 2008; 9(11): 1288–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. **F** Liao W, Spolski R, Li P, *et al.*: **Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression.** *Proc Natl Acad Sci U S A*. 2014; 111(9): 3508–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
23. **F** Laurence A, Tato CM, Davidson TS, *et al.*: **Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.** *Immunity*. 2007; 26(3): 371–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
24. Rosenberg SA: **IL-2: the first effective immunotherapy for human cancer.** *J Immunol*. 2014; 192(12): 5451–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Hou J, Schindler U, Henzel WJ, *et al.*: **An interleukin-4-induced transcription factor: IL-4 Stat.** *Science*. 1994; 265(5179): 1701–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Quelle FW, Shimoda K, Thierfelder W, *et al.*: **Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis.** *Mol Cell Biol*. 1995; 15(6): 3336–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Rolling C, Treton D, Pellegrini S, *et al.*: **IL4 and IL13 receptors share the gamma c chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells.** *FEBS Lett*. 1996; 393(1): 53–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. **F** Paul WE: **History of interleukin-4.** *Cytokine*. 2015; 75(1): 3–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
29. Aman MJ, Tayebi N, Obiri NI, *et al.*: **cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.** *J Biol Chem*. 1996; 271(46): 29265–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Demoulin JB, van Roost E, Stevens M, *et al.*: **Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9.** *J Biol Chem*. 1999; 274(36): 25855–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Rathmell JC, Farkash EA, Gao W, *et al.*: **IL-7 enhances the survival and maintains the size of naive T cells.** *J Immunol*. 2001; 167(12): 6869–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. **F** Opferman JT, Letai A, Beard C, *et al.*: **Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.** *Nature*. 2003; 426(6967): 671–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
33. Sprent J, Surh CD: **Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells.** *Nat Immunol*. 2011; 12(6): 478–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Fry TJ, Mackall CL: **Interleukin-7: from bench to clinic.** *Blood*. 2002; 99(11): 3892–904.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Melén E, Gullstén H, Zucchelli M, *et al.*: **Sex specific protective effects of interleukin-9 receptor haplotypes on childhood wheezing and sensitisation.** *J Med Genet*. 2004; 41(12): e123.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Lu Y, Hong S, Li H, *et al.*: **Th9 cells promote antitumor immune responses in vivo.** *J Clin Invest*. 2012; 122(11): 4160–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. **F** Purwar R, Schlapbach C, Xiao S, *et al.*: **Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.** *Nat Med*. 2012; 18(8): 1248–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
38. Waldmann TA: **The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.** *Nat Rev Immunol*. 2006; 6(8): 595–601.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Lodolce JP, Boone DL, Chai S, *et al.*: **IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.** *Immunity*. 1998; 9(5): 669–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Kennedy MK, Glaccum M, Brown SN, *et al.*: **Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.** *J Exp Med*. 2000; 191(5): 771–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Ozaki K, Spolski R, Ettinger R, *et al.*: **Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6.** *J Immunol*. 2004; 173(9): 5361–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Ettinger R, Sims GP, Fairhurst AM, *et al.*: **IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.** *J Immunol*. 2005; 175(12): 7867–79.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. **F** Zeng R, Spolski R, Finkelstein SE, *et al.*: **Synergy of IL-21 and IL-15 in regulating CD8⁺ T cell expansion and function.** *J Exp Med*. 2005; 201(1): 139–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
44. Vogelzang A, McGuire HM, Yu D, *et al.*: **A fundamental role for interleukin-21 in the generation of T follicular helper cells.** *Immunity*. 2008; 29(1): 127–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. **F** Korn T, Bettelli E, Gao W, *et al.*: **IL-21 initiates an alternative pathway to induce proinflammatory T_H17 cells.** *Nature*. 2007; 448(7152): 484–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
46. **F** Nurieva R, Yang XO, Martinez G, *et al.*: **Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.** *Nature*. 2007; 448(7152): 480–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
47. **F** Zhou L, Ivanov II, Spolski R, *et al.*: **IL-6 programs T_H17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.** *Nat Immunol*. 2007; 8(9): 967–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
48. Spolski R, Leonard WJ: **Interleukin-21: a double-edged sword with therapeutic potential.** *Nat Rev Drug Discov*. 2014; 13(5): 379–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Mehra P, Wells AD: **Long-Range Transcriptional Control of the IL2 Gene by an Intergenic Enhancer.** *Mol Cell Biol*. 2015; 35(22): 3880–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Park JH, Choi Y, Song MJ, *et al.*: **Dynamic Long-Range Chromatin Interaction Controls Expression of IL-21 in CD4⁺ T Cells.** *J Immunol*. 2016; 196(10): 4378–89.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. **F** Hinrichs CS, Spolski R, Paulos CM, *et al.*: **IL-2 and IL-21 confer opposing differentiation programs to CD8⁺ T cells for adoptive immunotherapy.** *Blood*. 2008; 111(11): 5326–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
52. **F** Ross SH, Rollins C, Anderson KE, *et al.*: **Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8⁺ T Cells.** *Immunity*. 2016; 45(3): 685–700.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
53. Huynh A, DuPage M, Priyadarshini B, *et al.*: **Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability.** *Nat Immunol*. 2015; 16(2): 188–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. **F** Oyler-Yaniv A, Oyler-Yaniv J, Whitlock BM, *et al.*: **A Tunable Diffusion-Consumption Mechanism of Cytokine Propagation Enables Plasticity in Cell-to-Cell Communication in the Immune System.** *Immunity*. 2017; 46(4): 609–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
55. Marks-Konczalik J, Dubois S, Losi JM, *et al.*: **IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.** *Proc Natl Acad Sci U S A*. 2000; 97(21): 11445–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. **F** Waldmann TA: **The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.** *Cancer Immunol Res*. 2015; 3(3): 219–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
57. **F** Su EW, Moore CJ, Suriano S, *et al.*: **IL-2R α mediates temporal regulation of IL-2 signaling and enhances immunotherapy.** *Sci Transl Med*. 2015; 7(311): 311ra170.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
58. **F** Hurton LV, Singh H, Najjar AM, *et al.*: **Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.** *Proc Natl Acad Sci U S A*. 2016; 113(48): E7788–E7797.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
59. **F** Arce Vargas F, Furness AJS, Solomon I, *et al.*: **Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1**

- Blockade to Eradicate Established Tumors.** *Immunity.* 2017; **46**(4): 577–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
60. Golgher D, Jones E, Powrie F, *et al.*: Depletion of CD25⁺ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. *Eur J Immunol.* 2002; **32**(11): 3267–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. Jones E, Dahm-Vicker M, Simon AK, *et al.*: Depletion of CD25⁺ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. *Cancer Immun.* 2002; **2**: 1.
[PubMed Abstract](#)
 62. Kalia V, Sarkar S, Subramaniam S, *et al.*: Prolonged interleukin-2R α expression on virus-specific CD8⁺ T cells favors terminal-effector differentiation *in vivo*. *Immunity.* 2010; **32**(1): 91–103.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 63. Pipkin ME, Sacks JA, Cruz-Guilloty F, *et al.*: Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. *Immunity.* 2010; **32**(1): 79–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 64. Rajagopalan A, Berezhnoy A, Schrand B, *et al.*: Aptamer-Targeted Attenuation of IL-2 Signaling in CD8⁺ T Cells Enhances Antitumor Immunity. *Mol Ther.* 2017; **25**(1): 54–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 65. Arenas-Ramirez N, Zou C, Popp S, *et al.*: Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. *Sci Transl Med.* 2016; **8**(367): 367ra166.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Spangler JB, Tomala J, Luca VC, *et al.*: Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms. *Immunity.* 2015; **42**(5): 815–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 67. Sun Y, Peng S, Yang A, *et al.*: Cojection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation. *Gene Ther.* 2017; **24**(7): 408–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 68. Levin AM, Bates DL, Ring AM, *et al.*: Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. *Nature.* 2012; **484**(7395): 529–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 69. Mitra S, Ring AM, Amarnath S, *et al.*: Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. *Immunity.* 2015; **42**(5): 826–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 70. Klatzmann D, Abbas AK: The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. *Nat Rev Immunol.* 2015; **15**(5): 283–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 71. He J, Zhang X, Wei Y, *et al.*: Low-dose interleukin-2 treatment selectively modulates CD4⁺ T cell subsets in patients with systemic lupus erythematosus. *Nat Med.* 2016; **22**(9): 991–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 72. Koreth J, Matsuoka K, Kim HT, *et al.*: Interleukin-2 and regulatory T cells in graft-versus-host disease. *N Engl J Med.* 2011; **365**(22): 2055–2066.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. Asano T, Meguri Y, Yoshioka T, *et al.*: PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. *Blood.* 2017; **129**(15): 2186–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 74. Lühthje K, Kallies A, Shimohakamada Y, *et al.*: The development and fate of follicular helper T cells defined by an IL-21 reporter mouse. *Nat Immunol.* 2012; **13**(5): 491–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 75. Reinhardt RL, Liang H, Locksley RM: Cytokine-secreting follicular T cells shape the antibody repertoire. *Nat Immunol.* 2009; **10**(4): 385–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. Weinstein JS, Herman EI, Lainez B, *et al.*: T_{PH} cells progressively differentiate to regulate the germinal center response. *Nat Immunol.* 2016; **17**(10): 1197–205.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 77. Jones L, Ho WQ, Ying S, *et al.*: A subpopulation of high IL-21-producing CD4⁺ T cells in Peyer's Patches is induced by the microbiota and regulates germinal centers. *Sci Rep.* 2016; **6**: 30784.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 78. Ballesteros-Tato A, Randall TD, Lund FE, *et al.*: T Follicular Helper Cell Plasticity Shapes Pathogenic T Helper 2 Cell-Mediated Immunity to Inhaled House Dust Mite. *Immunity.* 2016; **44**(2): 259–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 79. Pallikuth S, Parmigiani A, Silva SY, *et al.*: Impaired peripheral blood T-follicular helper cell function in HIV-infected nonresponders to the 2009 H1N1/09 vaccine. *Blood.* 2012; **120**(5): 985–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 80. Rao DA, Gurish MF, Marshall JL, *et al.*: Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. *Nature.* 2017; **542**(7639): 110–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 81. Linterman MA, Pierson W, Lee SK, *et al.*: Foxp3⁺ follicular regulatory T cells control the germinal center response. *Nat Med.* 2011; **17**(8): 975–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 82. Chung Y, Tanaka S, Chu F, *et al.*: Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. *Nat Med.* 2011; **17**(8): 983–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 83. Wollenberg I, Agua-Doce A, Hernández A, *et al.*: Regulation of the germinal center reaction by Foxp3⁺ follicular regulatory T cells. *J Immunol.* 2011; **187**(9): 4553–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 84. Sage PT, Ron-Harel N, Juneja VR, *et al.*: Suppression by T_{FR} cells leads to durable and selective inhibition of B cell effector function. *Nat Immunol.* 2016; **17**(12): 1436–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 85. Ballesteros-Tato A, León B, Graf BA, *et al.*: Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. *Immunity.* 2012; **36**(5): 847–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 86. Li J, Lu E, Yi T, *et al.*: EB12 augments T_H cell fate by promoting interaction with IL-2-queenching dendritic cells. *Nature.* 2016; **533**(7601): 110–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 87. Ray JP, Staron MM, Shyer JA, *et al.*: The Interleukin-2-mTORC1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells. *Immunity.* 2015; **43**(4): 690–702.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 88. Fontenot JD, Rasmussen JP, Gavin MA, *et al.*: A function for interleukin 2 in Foxp3-expressing regulatory T cells. *Nat Immunol.* 2005; **6**(11): 1142–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 89. León B, Bradley JE, Lund FE, *et al.*: FoxP3⁺ regulatory T cells promote influenza-specific T_H responses by controlling IL-2 availability. *Nat Commun.* 2014; **5**: 3495.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 90. Schmitz I, Schneider C, Fröhlich A, *et al.*: IL-21 restricts virus-driven Treg cell expansion in chronic LCMV infection. *PLoS Pathog.* 2013; **9**(5): e1003362.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 91. Attridge K, Wang CJ, Wardzinski L, *et al.*: IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. *Blood.* 2012; **119**(20): 4656–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 92. Jandl C, Liu SM, Cañete PF, *et al.*: IL-21 restricts T follicular regulatory T cell proliferation through Bcl-6 mediated inhibition of responsiveness to IL-2. *Nat Commun.* 2017; **8**: 14647.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 93. Kaplan MH, Hufford MM, Olson MR: The development and *in vivo* function of T helper 9 cells. *Nat Rev Immunol.* 2015; **15**(5): 295–307.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 94. Schmitt E, Germann T, Goedert S, *et al.*: IL-9 production of naive CD4⁺ T cells depends on IL-2, is synergistically enhanced by a combination of TGF- β and IL-4, and is inhibited by IFN- γ . *J Immunol.* 1994; **153**(9): 3989–96.
[PubMed Abstract](#)
 95. Bassil R, Orent W, Olah M, *et al.*: BCL6 controls Th9 cell development by repressing *Il9* transcription. *J Immunol.* 2014; **193**(1): 198–207.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 96. Gomez-Rodriguez J, Meylan F, Handon R, *et al.*: Itk is required for Th9 differentiation via TCR-mediated induction of IL-2 and IRF4. *Nat Commun.* 2016; **7**: 10857.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 97. Ulrich BJ, Verdan FF, McKenzie AN, *et al.*: STAT3 Activation Impairs the Stability of Th9 Cells. *J Immunol.* 2017; **198**(6): 2302–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 98. Végran F, Berger H, Boidot R, *et al.*: The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of T_H9 cells. *Nat Immunol.* 2014; **15**(8): 758–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
 99. Moretti S, Renga G, Oikonomou V, *et al.*: A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis. *Nat Commun.* 2017; **8**: 14017.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 100. Wan CK, Andraski AB, Spolski R, *et al.*: Opposing roles of STAT1 and STAT3 in IL-21 function in CD4⁺ T cells. *Proc Natl Acad Sci U S A.* 2015; **112**(30): 9394–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 101. Lin JX, Li P, Liu D, *et al.*: Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. *Immunity.* 2012; **36**(4): 586–99.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Michael Caligiuri**

The Ohio State University, Columbus, Ohio, USA

Competing Interests: No competing interests were disclosed.

2. **Thomas Malek**

Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, 33101, USA

Competing Interests: No competing interests were disclosed.

3. **Cecile King**

Immunology Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research